Article

RLE with new accommodative IOL offers good distance, near vision

Six-month results show 88% achieving 20/40 for distance, 70% achieving J3 or better

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
NICE approves idebenone for LHON in the UK
August 9th 2025

NICE approves idebenone for LHON in the UK

3 Things You Should Know About the GA Pipeline
August 9th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

SAHARA trial demonstrates sustained TearCare benefits for evaporative DED
August 9th 2025

SAHARA trial demonstrates sustained TearCare benefits for evaporative DED

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 9th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Viridian partners with Kissei Pharmaceutical to develop thyroid eye disease therapies in Japan
August 9th 2025

Viridian partners with Kissei Pharmaceutical to develop thyroid eye disease therapies in Japan

Clearside Biomedical's Xipere (triamcinolone acetonide injectable suspension) approved by Health Canada
August 9th 2025

Clearside Biomedical's Xipere (triamcinolone acetonide injectable suspension) approved by Health Canada

© 2025 MJH Life Sciences

All rights reserved.